Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care
醫療提供者在腎臟病和心力衰竭門診護理中採納血容量分析(BVA)
Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor's ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across hospitals and ambulatory care settings.
美國田納西州奧克里奇, 2024年12月18日 (全球資訊網) -- Daxor公司 (納斯達克: DXR),血容量測量技術的全球領導者,今天宣佈將其ezBVA實驗室服務擴展到兩個新的醫療系統。Daxor的ezBVA實驗室提供具有成本效益的血容量分析,提供全面的樣本處理,初始投資最低。該服務在醫院和門診護理環境中具有廣泛的報銷覆蓋。
New wins include:
新獲得的勝利包括:
- A major Arizona-based multi-campus medical center has adopted our BVA technology for outpatient nephrology care with further departments to follow in 2025.
- A regional health network serving communities across Southwest Iowa, Nebraska, Minnesota, and North Dakota has agreed to implement BVA for heart failure outpatient management.
- 一家總部位於亞利桑那州的大型多校區醫療中心已採用我們的BVA技術開展門診腎臟病護理,預計在2025年將進一步擴展至其他科室。
- 一個區域型衛生網絡爲服務於西南愛荷華州、內布拉斯加州、明尼蘇達州和北達科他州的社區已同意實施BVA以管理心力衰竭的門診護理。
"Our BVA platform is a critical diagnostic tool that redefines outpatient care by providing real-time insights into a patient's volume status. By enabling early detection of fluid imbalances and cardiovascular risks, BVA empowers clinicians to intervene proactively, potentially preventing costly hospitalizations, reducing emergency interventions, and personalizing patient treatment strategies," said John Jefferies, Daxor's Chief Medical Officer.
"我們的BVA平台是一個關鍵的診斷工具,重新定義了門診護理,通過提供患者體積狀態的實時洞察來實現。有助於提早發現液體失衡和心血管風險,BVA使臨床醫生能夠主動干預,從而可能防止昂貴的醫院入住,減少急救干預,並個性化患者治療策略," Daxor首席醫療官約翰·傑弗里斯說。
"The continued sales growth that the company is experiencing has positioned us for our best quarter ever in terms of revenue and year-over-year growth reflecting the focus of our commercialization team and the increasing customer engagement driven by our clinical education team," said Michael Feldschuh, Daxor's CEO and President.
"公司目前經歷的持續銷售增長使我們在營業收入和同比增長方面有望實現歷來最佳季度,這反映了我們商業化團隊的重點和我們臨床教育團隊推動的客戶參與日益增加," Daxor首席執行官兼總裁邁克爾·費爾施胡說。
About Daxor Corporation
關於Daxor公司
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology 在這裏.
Forward-Looking Statements
前瞻性聲明
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
本公告中的某些聲明可能包括1995年《私人證券訴訟改革法案》定義的前瞻性聲明,包括但不限於關於招聘銷售人員及擴展我們分銷渠道影響的聲明。前瞻性聲明是關於未來事件的預測、項目和其他聲明,這些聲明基於當前的期望和假設,因此受到風險和不確定性的影響。許多因素可能導致實際未來事件與本公告中的前瞻性聲明存在重大差異,包括但不限於與我們的上市後臨床數據收集活動相關的風險、我們的產品對患者的益處、我們對產品開發和商業化努力的期望、我們增加市場和醫生接受我們產品能力的能力、潛在的競爭產品提供、知識產權保護、FDA監管措施、我們整合收購業務的能力、我們對預期協同效應及從收購業務中獲得的利益的期望,以及在我們向SEC提交的文件中描述的其他風險和不確定性。前瞻性聲明僅在作出時有效。Daxor不承擔任何義務公開更新或修訂任何前瞻性聲明,無論是由於新信息、未來事件還是其他原因。
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
投資者關係聯繫:
佈雷特·夏皮羅
高級管理合夥人,核心投資關係
1-516-222-2560
brets@coreir.com
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因